Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX-SRS in Borderline Resectable Pancreatic Cancer
NCT00833859Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2009
- Primary completion
- Mar 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, docetaxel, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Moffitt Cancer Center. Started Mar 2009; status: terminated.
02
Drugs
capecitabinedocetaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00833859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833859.